Bayer Aktiengesellschaft (BAYRY) Expected to Announce Earnings on Tuesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is anticipated to release its results before the market opens on Tuesday, November 11th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.13 per share and revenue of $11.3055 billion for the quarter.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.10. The company had revenue of $12.42 billion for the quarter, compared to analysts’ expectations of $10.79 billion. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Trading Up 1.1%

Shares of OTCMKTS BAYRY traded up $0.08 during midday trading on Tuesday, reaching $7.64. 172,673 shares of the stock were exchanged, compared to its average volume of 719,069. The business has a 50-day simple moving average of $8.08 and a two-hundred day simple moving average of $7.66. The company has a market capitalization of $30.02 billion, a price-to-earnings ratio of -7.88, a P/E/G ratio of 3.62 and a beta of 0.90. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $8.70. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 30th. Three investment analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Strong Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.